Cambridge biotech Sarepta Therapeutics Inc. said Wednesday it has named industry veteran Douglas S. Ingram as its new chief executive and a company director.
Ingram will repace Edward M. Kaye, who recently announced he would step down from the top job at Sarepta, which last year won Food and Drug Administration approval of a drug to treat the rare disease Duchenne muscular dystrophy. Kaye will continue to advise the company
The new Sarepta chief executive was formerly president of Allergan Inc., a drug company acquired in 2015 by Actavis PLC, which took the Allergan name. Most recently, Ingram was chief executive of Chase Pharmaceuticals, a biopharmaceutical company developing treatments for neurodegenerative disorders. That company was acquired by Allergan last year.